Antibodies

Alternatives in HD treatment: RNA interference, small molecules, and combination approaches 5:14
Alternatives in HD treatment: RNA interference, small molecules, and combination approaches
Jee Bang • 4 Apr 2022
Important lines of research in progressive multiple sclerosis 2:54
Important lines of research in progressive multiple sclerosis
Lawrence Steinman • 11 Apr 2022
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab 1:12
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab
Lilyana Amezcua • 4 Apr 2022
Diagnostic work up of autoimmune neurological conditions 3:13
Diagnostic work up of autoimmune neurological conditions
Divyanshu Dubey • 12 Apr 2022
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS 1:52
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS
Lawrence Steinman • 11 Apr 2022
Immunotherapy strategies for autoimmune disorders of the nervous system 1:43
Immunotherapy strategies for autoimmune disorders of the nervous system
Divyanshu Dubey • 12 Apr 2022
AOCs: future outlooks in other disease areas 1:46
AOCs: future outlooks in other disease areas
Arthur Levin • 6 Apr 2022
Optimization of myasthenia gravis management: knowledge gaps 3:24
Optimization of myasthenia gravis management: knowledge gaps
James F. Howard Jr. • 12 Apr 2022
AOC for the treatment of Duchenne muscular dystrophy in exon 44 skippers 1:52
AOC for the treatment of Duchenne muscular dystrophy in exon 44 skippers
Arthur Levin • 6 Apr 2022
AOC programs in development for DMD and myotonic dystrophy 4:27
AOC programs in development for DMD and myotonic dystrophy
Arthur Levin • 6 Apr 2022
Complement inhibitor therapy for myasthenia gravis: current and future outlooks 2:52
Complement inhibitor therapy for myasthenia gravis: current and future outlooks
James F. Howard Jr. • 12 Apr 2022
Discontinuation and reinitiation of migraine treatment with GCRP mAbs 1:12
Discontinuation and reinitiation of migraine treatment with GCRP mAbs
Uwe Reuter • 25 Jun 2022
AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation 6:02
AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation
Klaus Schmierer • 1 Jul 2022
Personalized B-cell tailored dosing of ocrelizumab in MS 0:56
Personalized B-cell tailored dosing of ocrelizumab in MS
Alyssa Toorop • 26 Jun 2022
Updates on natalizumab and anti-CD20 antibodies for MS 2:21
Updates on natalizumab and anti-CD20 antibodies for MS
Massimo Filippi • 26 Jun 2022
REGAIN trial of galcanezumab in chronic migraine 1:18
REGAIN trial of galcanezumab in chronic migraine
Uwe Reuter • 25 Jun 2022
The content of VJNeurology is intended for healthcare professionals